Novartis

Traded on the St. Petersburg Stock Exchange
Novartis International is a Swiss multinational pharmaceutical company. It is the second largest pharmaceutical company in the world by market capitalization in 2019. The company was founded in 1895 by the merger of the Swiss companies Ciba-Geigy and Sandoz Laboratories, and is headquartered in Basel, Switzerland.
Novartis stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Novartis balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Novartis cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Novartis multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Novartis profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Novartis assets
Novartis cash flows
Novartis dividends
0%

Novartis dividend policy

The сompany provides dividend once a year

Novartis shares

TickerNameTypeNominal valueISINPrice
NVS:USNovartisCommon share-US66987V1098$103.5
NOVN:SWNovartisCommon share-CH0012005267CHF 91.71
Novartis news
24.10.2023
Novartis' IFRS net income for 9 months of 2023 amounted to $6.374 billion, up 16.1% from $5.489 billion in the previous year. Revenue increased by 7.5% to $34.017 bln vs. $31.63 bln a year earlier.
Source: {source} pictogram novartis.com
Pictogram next
18.07.2023
Novartis IFRS net income for 6 months of 2023 amounted to $4.611 billion, up 17.8% from $3.914 billion in the previous year. Revenue increased 5% to $26.575 billion from $25.312 billion a year earlier.
Source: {source} pictogram novartis.com
Pictogram next
25.04.2023
Novartis' IFRS net income for 3 months of 2022 was $2.294 billion, up 3.4% from $2.219 billion in the previous year. Revenue increased by 3.4% to $12.953 billion against $12.531 billion a year earlier.
Source: {source} pictogram novartis.com
Pictogram next
01.02.2023
Novartis' IFRS net income for 2022 was $6.955 billion, down 19.7% from $8.661 billion in the previous year. Revenue decreased by 2.1% to $50.545 billion from $51.626 billion a year earlier.
Source: {source} pictogram novartis.com
Pictogram next
All Novartis news
General information
Company nameNovartis
Tags#pharmacy, #katie wood's choice
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressLICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
Mailing addressLICHTSTRASSE 35 BASEL V8 CH 4056
Websitewww.novartis.com
Information disclosurewww.sec.gov